---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000031"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:15:14.746111+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Supernus to present interim Phase IIa data for SPN-817 on May 23

## Summary
- Interim data from open-label Phase IIa study of SPN-817 for treatment-resistant seizures to be reviewed at webcast on May 23, 2024.
- Webcast at 4:30 p.m. ET; replay and slides available for 60 days via company website.
- No actual clinical results disclosed in this filing; full data release scheduled for the event.

## SEC filing metadata
- accession: 0001356576-24-000031
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000031/0001356576-24-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000031/supn-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000031
- JSON: https://secwatch.observer/filing/0001356576-24-000031.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.